Clinical trials: TACE
Cancer
Effectiveness of Knowledge by Video and Handbook of Liver Cancer Patients With First Trans-arterial Chemoembolization
Objective: To compare the effectiveness between Video and Handbook on providing knowledge of TACE. Study Design: A prospective, randomized, controlled trial.
- Trial name
- NCT02768428
- Testing
- Video-Audio Media
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chulabhorn Hospital
Carcinoma, Hepatocellular
Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma
Developed in Japan in the 1980s, TACE became the most frequent treatment for unresectable hepatocellular carcinoma (HCC) in patients with preserved hepatic function after 2002, when two radiochemotherapies (RCTs) showed survival…
- Trial name
- RAD-18-TAcE (NCT04803019)
- Testing
- DEB-TACE, TAE
- Where
- Italy
- Volunteers
- 154 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma
Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver that accounts for an important health problem worldwide. In only 10% - 15% of all patients with HCC, tumors are considered resectable at presentation.
- Trial name
- TRACE (NCT01381211)
- Testing
- TACE-DEB, 90Y-RE
- Where
- Belgium
- Volunteers
- 72 people
- Sponsor
- University Hospital, Ghent
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced…
- Conditions
- Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
- Trial name
- NCT05984511
- Testing
- I-125 Seeds Brachytherapy in PVTT, Transcatheter arterial chemoembolization, Atezolizumab plus Bevacizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Adjuvant Radiotherapy Comparing TACE for Curative HCC
Despite advances in our understanding of hepatocellular carcinoma (HCC) and its diagnosis, the prognosis for patients with HCC remains disheartening, due to a high recurrence rate and frequent intrahepatic metastasis.
- Trial name
- ARTC-HCC (NCT02125396)
- Testing
- Transarterial chemoembolization, Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Liver Cell Carcinoma Non-resectable
Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer in men and the seventh in women and is the third most common cause of death from cancer worldwide.
- Trial name
- DEBDOX (NCT01891539)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Hepatocellular Carcinoma
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of tumor mortality in China, posing a serious threat to the lives and health of the Chinese people .
- Trial name
- NCT06272656
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hebei Medical University Third Hospital
Hepatocellular Carcinoma
RCT on Adjuvant TACE After Hepatectomy for HCC
We hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival.
- Trial name
- A-TECH (NCT01512407)
- Testing
- Transarterial chemoembolisation using cisplatin-lipiodol mixture
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma, Chemoembolization
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation.
- Trial name
- NCT02147301
- Testing
- LC Bead
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis
The purpose of this study is to investigate safety and potential therapeutic benefits for patients with hepatocellular carcinoma by transcatheter chemoembolization with the recombinant endostatin (commercially available in…
- Trial name
- TACE HCC (NCT00518557)
- Testing
- Transcatheter Arterial Chemoembolization
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Southeast University, China
Hepatocellular Carcinoma Non-resectable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
- Trial name
- ASTrH (NCT04996914)
- Testing
- TACE, SBRT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- RWTH Aachen University
Hepatocellular Carcinoma
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80% patients receive a diagnosis when their tumors are too advanced for curative approaches and have a dismal prognosis.
- Trial name
- NCT04011033
- Testing
- iNKT cells, Human recombinated Interleukin-2, TAE/TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing YouAn Hospital
HCC - Hepatocellular Carcinoma
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants with incurable/non-metastatic HCC.
- Trial name
- NCT07521852
- Testing
- CVM-1118 + Sintilimab + TACE
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- TaiRx, Inc.
Hepatocellular Carcinoma, Liver Neoplasms
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
This single-center, prospective study evaluates the therapeutic outcomes of saline-augmented bipolar radiofrequency ablation (RFA) with twin internally cooled-perfusion (TICP) electrodes for treating recurrent hepatocellular…
- Trial name
- ERFA (NCT07192172)
- Testing
- Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer
This is a randomized, open-label, active comparator-controlled trial of subjects with advanced (Barcelona stage B/C) hepatocellular carcinoma.
- Trial name
- TACE-SBRT (NCT02304445)
- Testing
- Transarterial Chemoembolization (TACE), TACE+Stereotactic Body Radiotherapy
- Sponsor
- Juan Sanabria, MD
Hepatocellular Carcinoma
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC.
- Trial name
- NCT03066557
- Testing
- TACE and Apatinib, TACE
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Metastatic Prostate Cancer, Prostate Cancer
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic…
- Trial name
- NCT07145177
- Testing
- 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.
- Trial name
- NCT04559607
- Testing
- Camrelizumab, TACE, Apatinib
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital